Midregional pro-adrenomedullin plasma concentrations are blunted in severe preeclampsia

Abstract

Levels of the peptide hormone adrenomedullin (AM) are elevated during normal pregnancy, but whether this differs during complications of pregnancy remains unresolved. AM can be quantified by measuring its preprohormone byproduct, midregional pro-adrenomedullin (MR-proADM). MR-pro ADM has shown prognostic value as a biomarker of heart failure, sepsis, and community-acquired pneumonia. Given the relevance of AM to pregnancy, we tested the hypothesis that MR-proADM provides a biomarker for preeclampsia. We find that MR-proADM plasma concentrations are blunted in severe preeclampsia and that MR-proADM is similarly effective as established biomarkers endoglin and placental growth factor at discriminating patients with severe preeclampsia from controls.

Cardiovascular Biomarkers in Amniotic Fluid, Umbilical Arterial Blood, Umbilical Venous Blood, and Maternal Blood at Delivery, and Their Reference Values for Full-Term, Singleton, Cesarean Deliveries

“…Alternatively, fetal renal excretion into the AF might have occurred. Higher MRproADM levels in multiple pregnancies with a relatively larger amount of total placental tissue, as shown in our study (Table 5), and lower levels in placental insufficiency (18) support a placental origin of MRproADM.…”

Hyperoxia exposure disrupts adrenomedullin signaling in newborn mice: Implications for lung development in premature infants

“…Recently, AM signaling is increasingly been recognized as a necessary pathway for vascular remodeling and immune response in physiological states such as pregnancy [23], and disrupted AM signaling is shown to contribute to several pathophysiological states such as preeclampsia [24], systemic and pulmonary hypertension [25, 26], myocardial infarction [27], tumors [28], and lymphedema [29]. Further, Calcrl-RAMP complexes are being explored as important drug targets to treat acute myocardial infarction, pulmonary hypertension, migraine headache, cancer, and several other disorders [30–32], indicating that AM signaling axis can be targeted to develop therapies.…”

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

“…92,93 Biomarkers for HFpEF and preeclampsia Two studies on MRproADM described significantly higher levels in pre-eclampsia vs. controls. 95,96 Two studies on c-Tn1 described elevated levels in preeclampsia compared with controls, 97,98 of which only one with statistically significant result. 97 Tumour angiogenesis markers in pre-eclampsia Cancer antigen 125 and carcino-embryonic antigen Three studies reported on CA-125 levels in pre-eclampsia vs. controls, 26,99,100 of which two studies described significantly lower CA-125 levels in PE 99,26 and one did not show significantly different CA-125 levels between pre-eclampsia and controls.…”